Literature DB >> 30943503

Natural History of Treated and Untreated Hypopharyngeal Cancer.

Hans E Eckel1, Patrick J Bradley2.   

Abstract

Patients with hypopharyngeal cancers frequently present at advanced stage and in poor general health status. Their natural history is characterised by diffuse local primary disease, mucosal and submucosal spread, early cervical nodal metastasis, and a relatively high rate of distant spread. By the time of initial diagnosis, some 60% of all hypopharyngeal cancer patients will be with stage IV disease, some 5% will present with distant metastases, and almost 40% will have a significant reduction in performance status. Less than 20% are diagnosed with a localised early stage disease. A long-standing social habit of excess of alcohol and tobacco usage leads to cancerisation and accounts for the multiple, synchronous primary malignant lesions that occur in many hypopharyngeal cancer patients. The natural history of untreated head and neck squamous cell carcinoma has infrequently been documented in the medical literature. However, without understanding the natural history of hypopharyngeal cancer, patient counselling and clinical management are difficult. Less than 20% of untreated patients survive for > 12 months and only a small proportion of patients will survive for more than 2 years after initial diagnosis. The natural course of the disease in patients treated for cure or, at least, for the relief of symptoms, is certainly more favourable than that of those who are not suited for, or not willing to accept the adverse effects of treatment. However, treatment results are still considerably less encouraging than those that are being reported for other sub-sites of the head and neck region. Among all head and neck cancer sites, 5-year age-standardised relative survival is currently the poorest for cancer of the hypopharynx and the highest for larynx cancers, 25 and 59%, respectively. Among the head and neck cancers, only hypopharynx showed a low outcome (25% at 5 years), with survival figures ranging between ≤30 (North Ireland and Italy) and 8% (Bulgaria). Recent studies from the United States indicate that overall 5-year survival rates for hypopharyngeal cancer have improved significantly in recent years, with the average survival being ≥40%.
© 2019 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2019        PMID: 30943503     DOI: 10.1159/000492305

Source DB:  PubMed          Journal:  Adv Otorhinolaryngol        ISSN: 0065-3071


  5 in total

1.  Nomograms predicting prognosis for locally advanced hypopharyngeal squamous cell carcinoma.

Authors:  Huiyun Yang; Mengsi Zeng; Sudan Cao; Long Jin
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-10-14       Impact factor: 3.236

2.  A pathogenic germline BRCA2 variant in a patient with hypopharyngeal squamous cell carcinoma.

Authors:  Tatiana Correa; Douglas E Laux; Henry T Hoffman
Journal:  Clin Case Rep       Date:  2020-11-25

3.  A Novel Overall Survival Nomogram Prediction of Secondary Primary Malignancies after Hypopharyngeal Cancer: A Population-Based Study.

Authors:  Meng Wan; Dan Zhao; Yan Sun; Weihu Wang
Journal:  J Oncol       Date:  2022-04-28       Impact factor: 4.375

4.  Prognostic Nomogram for Postoperative Hypopharyngeal Squamous Cell Carcinoma to Assist Decision Making for Adjuvant Chemotherapy.

Authors:  Di Zhang; Lixi Li; Tingyu Wen; Yun Wu; Fei Ma
Journal:  J Clin Med       Date:  2022-09-30       Impact factor: 4.964

5.  Myosin light chain kinase is a potential target for hypopharyngeal cancer treatment.

Authors:  Feng Cao; Le Zhu; Jing Zhang; Pawin Pongkorpsakol; Wei-Ting Kuo; Jerrold R Turner; Qing Zhou; Yuan Wang; Feihu Chen; Yehai Liu; Li Zuo
Journal:  Biomed Pharmacother       Date:  2020-09-10       Impact factor: 6.529

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.